UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 65

Sortiert nach

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Lancet neurology, 2012-07, Vol.11 (7), p.597-604

2012

Volltextzugriff (PDF)

Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion

Nature genetics, 1997-09, Vol.17 (1), p.65-70

1997

Volltextzugriff (PDF)

Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias

Nature (London), 1995-11, Vol.378 (6555), p.403-406

1995

Volltextzugriff (PDF)

Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form

Nature genetics, 1995-05, Vol.10 (1), p.104-110

1995

Volltextzugriff (PDF)

Democratizing data at Novartis through clinical trial data access

Drug discovery today, 2022-06, Vol.27 (6), p.1533-1537

2022

Volltextzugriff (PDF)

The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity

Genes & development, 1999-07, Vol.13 (14), p.1822-1833

1999

Volltextzugriff (PDF)

Controlled Protein Precipitation in Combination with Chip-Based Nanospray Infusion Mass Spectrometry. An Approach for Metabolomics Profiling of Plasma

Analytical chemistry (Washington), 2005-11, Vol.77 (22), p.7255-7264

2005

Volltextzugriff (PDF)

Dose‐dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship

Epilepsia (Copenhagen), 2015-06, Vol.56 (6), p.924-932

2015

Volltextzugriff (PDF)

The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity

Genes & development, 1999-07, Vol.13 (14), p.1822-1833

1999

Volltextzugriff (PDF)

Differential distribution of the normal and mutated forms of huntingtin in the human brain

Annals of neurology, 1997-11, Vol.42 (5), p.712-719

1997

Volltextzugriff (PDF)

Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats

Nature genetics, 1996-11, Vol.14 (3), p.285-291

1996

Volltextzugriff (PDF)

Safety, tolerability, and antibody response of active A[Beta] immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Lancet neurology, 2012-07, Vol.11 (7), p.597

2012

Volltextzugriff (PDF)

Antibody immune response in cynomolgus monkeys following treatment with the active Aß immunotherapy CAD106

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P427-P427

2009

Volltextzugriff (PDF)

P3‐285: Antibody immune response in cynomolgus monkeys following treatment with the active Aß immunotherapy CAD106

Alzheimer's & dementia, 2009-07, Vol.5 (4S_Part_14), p.P427-P427

2009

Volltextzugriff (PDF)

P3‐294: The active Aβ immunotherapy CAD106 increases plasma Aβ in monkeys

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_17), p.S537-S538

2010

Volltextzugriff (PDF)

The active Aβ immunotherapy CAD106 increases plasma Aβ in monkeys

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S537-S538

2010

Volltextzugriff (PDF)

Aβ-specific antibodies induced by active immunotherapy CAD106 engage Aβ in plasma in AD patients

Alzheimer's & dementia, 2011-07, Vol.7 (4), p.S334-S334

2011

Volltextzugriff (PDF)

P2‐083: Aβ‐specific antibodies induced by active immunotherapy CAD106 engage Aβ in plasma in AD patients

Alzheimer's & dementia, 2011-07, Vol.7 (4S_Part_10), p.S334-S334

2011

Volltextzugriff (PDF)

Molecular and Clinical Correlations in Spinocerebellar Ataxia 2: A Study of 32 Families

Human molecular genetics, 1997-05, Vol.6 (5), p.709-715

1997

Volltextzugriff (PDF)

Origin of the expansion mutation in myotonic dystrophy

Nature genetics, 1993-05, Vol.4 (1), p.72-76

1993

Volltextzugriff (PDF)

Optimization of the treatment regimen with active Aß immunotherapy CAD106 in alzheimer patients

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S532-S532

2010

Volltextzugriff (PDF)

P3‐275: Optimization of the treatment regimen with active Aß immunotherapy CAD106 in alzheimer patients

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_17), p.S532-S532

2010

Volltextzugriff (PDF)

Inheritance of the fragile X syndrome: size of the fragile X premutation is a major determinant of the transition to full mutation

Journal of medical genetics, 1992-11, Vol.29 (11), p.794-801

1992

Volltextzugriff (PDF)

The Gene for the TATA Binding Protein (TBP) That Contains a Highly Polymorphic Protein Coding CAG Repeat Maps to 6q27

Genomics (San Diego, Calif.), 1994-06, Vol.21 (3), p.667-668

1994

Volltextzugriff (PDF)

Screening for Proteins with Polyglutamine Expansions in Autosomal Dominant Cerebellar Ataxias

Human molecular genetics, 1996-12, Vol.5 (12), p.1887-1892

1996

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(63)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion

Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias

Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form

Democratizing data at Novartis through clinical trial data access

The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity

Controlled Protein Precipitation in Combination with Chip-Based Nanospray Infusion Mass Spectrometry. An Approach for Metabolomics Profiling of Plasma

Dose‐dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship

The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity

Differential distribution of the normal and mutated forms of huntingtin in the human brain

Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats

Safety, tolerability, and antibody response of active A[Beta] immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Antibody immune response in cynomolgus monkeys following treatment with the active Aß immunotherapy CAD106

P3‐285: Antibody immune response in cynomolgus monkeys following treatment with the active Aß immunotherapy CAD106

P3‐294: The active Aβ immunotherapy CAD106 increases plasma Aβ in monkeys

The active Aβ immunotherapy CAD106 increases plasma Aβ in monkeys

Aβ-specific antibodies induced by active immunotherapy CAD106 engage Aβ in plasma in AD patients

P2‐083: Aβ‐specific antibodies induced by active immunotherapy CAD106 engage Aβ in plasma in AD patients

Molecular and Clinical Correlations in Spinocerebellar Ataxia 2: A Study of 32 Families

Origin of the expansion mutation in myotonic dystrophy

Optimization of the treatment regimen with active Aß immunotherapy CAD106 in alzheimer patients

P3‐275: Optimization of the treatment regimen with active Aß immunotherapy CAD106 in alzheimer patients

Inheritance of the fragile X syndrome: size of the fragile X premutation is a major determinant of the transition to full mutation

The Gene for the TATA Binding Protein (TBP) That Contains a Highly Polymorphic Protein Coding CAG Repeat Maps to 6q27

Screening for Proteins with Polyglutamine Expansions in Autosomal Dominant Cerebellar Ataxias

Suchergebnisse filtern